&lt;i&gt;TET2&lt;/i&gt; mutational status affects myelodysplastic syndrome evolution to chronic myelomonocytic leukemia

Quang, Violaine Tran; Podvin, Benjamin; Desterke, Christophe; Tarfi, Sihem; Barathon, Quentin; Badaoui, Bouchra; Freynet, Nicolas; Parinet, Vincent; Leclerc, Mathieu; Maury, Sébastien; Solary, Éric; Selimoglu-Buet, Dorothée; Duployez, Nicolas; Wagner‐Ballon, Orianne; Sloma, Ivan

doi:10.3324/haematol.2022.282528

Cited by 3 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Associated to this phenotypic feature, more recent studies demonstrated that this MDS subset is characterized by bi-allelic TET2 inactivation (Quang et al, 2023) such as OM-CMML (Calvo et al, 2022). All these data revisit the boundaries between MDS and MDS/MPN.…”

Section: Feasibility On Bone Marrow Samplesmentioning

confidence: 77%

“…These patients share typical features of CMML and CMML-related molecular features, such as TET2 and SRSF2 mutations and some have prominent bone marrow monocytosis (Geyer et al, 2017;Schuler et al, 2018;Valent et al, 2019). Both recent classifications, the fifth revised WHO classification (Khoury et al, 2022) and ICC (Arber et al, 2022), have lowered this historical threshold (Bennett et al, 1976) into genuine CMML (Quang et al, 2023;Selimoglu-Buet et al, 2017).…”

Section: Feasibility On Bone Marrow Samplesmentioning

confidence: 99%

“…Alongside, our group and Padron's team have demonstrated that roughly one third of MDS patients at diagnosis displayed a relative accumulation of cMo above 94% at diagnosis, regardless of monocytosis value (Selimoglu‐Buet et al, 2017; Talati et al, 2017). Half of the “CMML‐like MDS” patients, whose progenitors exhibit increased sensitivity to GM‐CSF (Quang et al, 2023) such as CMML ones, evolved into genuine CMML (Quang et al, 2023; Selimoglu‐Buet et al, 2017). Associated to this phenotypic feature, more recent studies demonstrated that this MDS subset is characterized by bi‐allelic TET2 inactivation (Quang et al, 2023) such as OM‐CMML (Calvo et al, 2022).…”

Section: Part 3: Perspectivesmentioning

confidence: 99%

“…Half of the “CMML‐like MDS” patients, whose progenitors exhibit increased sensitivity to GM‐CSF (Quang et al, 2023) such as CMML ones, evolved into genuine CMML (Quang et al, 2023; Selimoglu‐Buet et al, 2017). Associated to this phenotypic feature, more recent studies demonstrated that this MDS subset is characterized by bi‐allelic TET2 inactivation (Quang et al, 2023) such as OM‐CMML (Calvo et al, 2022). All these data revisit the boundaries between MDS and MDS/MPN.…”

Section: Part 3: Perspectivesmentioning

confidence: 99%

mentioning

confidence: 96%

See 4 more Smart Citations

Technical, gating and interpretation recommendations for the partitioning of circulating monocyte subsets assessed by flow cytometry

Tarfi,

Kern,

Goulas

et al. 2024

Cytometry Part B Clinical

Self Cite

View full text Add to dashboard Cite

The monocyte subset partitioning by flow cytometry, known as “monocyte assay,” is now integrated into the new classifications as a supporting criterion for CMML diagnosis, if a relative accumulation of classical monocytes above 94% of total circulating monocytes is observed. Here we provide clinical flow cytometry laboratories with technical support adapted for the most commonly used cytometers. Step‐by‐step explanations of the gating strategy developed on whole peripheral blood are presented while underlining the most common difficulties. In a second part, interpretation recommendations of circulating monocyte partitioning from the dedicated French working group “CytHem‐LMMC” are shared as well as the main pitfalls, including false positive and false negative cases. The particular flow‐defined inflammatory profile is described and the usefulness of the nonclassical monocyte specific marker, namely slan, highlighted. Examples of reporting to the physician with frequent situations encountered when using the monocyte assay are also presented.

show abstract

Section: Feasibility On Bone Marrow Samplesmentioning

confidence: 77%

Section: Feasibility On Bone Marrow Samplesmentioning

confidence: 99%

Section: Part 3: Perspectivesmentioning

confidence: 99%

Section: Part 3: Perspectivesmentioning

confidence: 99%

mentioning

confidence: 96%

See 3 more Smart Citations

Technical, gating and interpretation recommendations for the partitioning of circulating monocyte subsets assessed by flow cytometry

Tarfi,

Kern,

Goulas

et al. 2024

Cytometry Part B Clinical

Self Cite

View full text Add to dashboard Cite

show abstract

Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia

Tran Quang,

Wagner-Ballon,

Sloma

2024

Leukemia & Lymphoma

View full text Add to dashboard Cite

A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms

Abdulbaki,

Pullarkat

2024

Current Oncology

View full text Add to dashboard Cite

Myelodysplastic neoplasm (MDS) is a heterogeneous group of clonal hematological disorders that originate from the hematopoietic and progenitor cells and present with cytopenias and morphologic dysplasia with a propensity to progress to bone marrow failure or acute myeloid leukemia (AML). Genetic evolution plays a critical role in the pathogenesis, progression, and clinical outcomes of MDS. This process involves the acquisition of genetic mutations in stem cells that confer a selective growth advantage, leading to clonal expansion and the eventual development of MDS. With the advent of next-generation sequencing (NGS) assays, an increasing number of molecular aberrations have been discovered in recent years. The knowledge of molecular events in MDS has led to an improved understanding of the disease process, including the evolution of the disease and prognosis, and has paved the way for targeted therapy. The 2022 World Health Organization (WHO) Classification and the International Consensus Classification (ICC) have incorporated the molecular signature into the classification system for MDS. In addition, specific germline mutations are associated with MDS development, especially in pediatrics and young adults. This article reviews the genetic abnormalities of MDS in adults with a brief review of germline predisposition syndromes.

show abstract

<i>TET2</i> mutational status affects myelodysplastic syndrome evolution to chronic myelomonocytic leukemia

Abstract: Not available.

Cited by 3 publications

References 15 publications

Technical, gating and interpretation recommendations for the partitioning of circulating monocyte subsets assessed by flow cytometry

Technical, gating and interpretation recommendations for the partitioning of circulating monocyte subsets assessed by flow cytometry

Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia

A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms

Contact Info

Product

Resources

About